PT1781787T - Tratamento de distúrbios oculares caracterizados por uma pressão intraocular elevada por meio de arnsis - Google Patents

Tratamento de distúrbios oculares caracterizados por uma pressão intraocular elevada por meio de arnsis

Info

Publication number
PT1781787T
PT1781787T PT57812646T PT05781264T PT1781787T PT 1781787 T PT1781787 T PT 1781787T PT 57812646 T PT57812646 T PT 57812646T PT 05781264 T PT05781264 T PT 05781264T PT 1781787 T PT1781787 T PT 1781787T
Authority
PT
Portugal
Prior art keywords
sirnas
treatment
intraocular pressure
disorders characterized
eye disorders
Prior art date
Application number
PT57812646T
Other languages
English (en)
Inventor
I Jimenez Ana
Sesto Ángela
P Román José
Gascón Irene
González De Buitrago Gonzalo
Original Assignee
Sylentis Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35967904&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1781787(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0418762.1A external-priority patent/GB0418762D0/en
Priority claimed from GB0503412A external-priority patent/GB0503412D0/en
Application filed by Sylentis Sau filed Critical Sylentis Sau
Publication of PT1781787T publication Critical patent/PT1781787T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
PT57812646T 2004-08-23 2005-08-23 Tratamento de distúrbios oculares caracterizados por uma pressão intraocular elevada por meio de arnsis PT1781787T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0418762.1A GB0418762D0 (en) 2004-08-23 2004-08-23 Methods and compositions to treat glaucoma
GB0503412A GB0503412D0 (en) 2005-02-18 2005-02-18 Methods and compositions to treat glaucoma

Publications (1)

Publication Number Publication Date
PT1781787T true PT1781787T (pt) 2017-07-17

Family

ID=35967904

Family Applications (1)

Application Number Title Priority Date Filing Date
PT57812646T PT1781787T (pt) 2004-08-23 2005-08-23 Tratamento de distúrbios oculares caracterizados por uma pressão intraocular elevada por meio de arnsis

Country Status (17)

Country Link
US (11) US8030284B2 (pt)
EP (3) EP2292757A3 (pt)
JP (2) JP5766900B2 (pt)
CN (2) CN105251024A (pt)
AU (1) AU2005276245C1 (pt)
CA (1) CA2578064C (pt)
CY (1) CY1119061T1 (pt)
DK (1) DK1781787T3 (pt)
ES (1) ES2632913T3 (pt)
HR (1) HRP20171010T8 (pt)
HU (1) HUE033977T2 (pt)
LT (1) LT1781787T (pt)
PL (1) PL1781787T3 (pt)
PT (1) PT1781787T (pt)
RU (1) RU2407531C2 (pt)
SI (1) SI1781787T1 (pt)
WO (1) WO2006021817A2 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
PL1781787T3 (pl) * 2004-08-23 2018-01-31 Sylentis Sau Leczenie zaburzeń oka charakteryzowanych przez podwyższone ciśnienie wewnątrzgałkowe przy użyciu siRNA
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
WO2006094014A2 (en) 2005-02-28 2006-09-08 The Regents Of The University Of California Methods for diagnosis and treatment of endometrial cancer
US8648052B2 (en) * 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
WO2006113526A2 (en) 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
GB0521716D0 (en) * 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
US8673873B1 (en) * 2005-12-28 2014-03-18 Alcon Research, Ltd. RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
CN101426914A (zh) * 2005-12-30 2009-05-06 因特拉迪格姆公司 促进皮肤的无疤痕伤口痊愈的siRNA组合物以及用于伤口治疗的方法
ATE456053T1 (de) * 2005-12-30 2010-02-15 Ventana Med Syst Inc Na+, k+-atpase-expression bei zervixdysplasie und krebs
WO2008023840A2 (en) 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
AU2006350507A1 (en) * 2006-11-09 2008-05-15 Unibioscreen S.A. Targeting of alpha-1 or alpha-3 subunit of Na+, K+-ATPase in the treatment of proliferative diseases
EP2468886A1 (en) 2006-12-13 2012-06-27 Oncotherapy Science, Inc. TTK as tumor marker and therapeutic target for lung cancer
CN101835893A (zh) 2007-08-24 2010-09-15 肿瘤疗法科学股份有限公司 癌症相关基因cdca5、epha7、stk31和wdhd1
WO2009028580A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
WO2011063161A2 (en) 2009-11-20 2011-05-26 The Regents Of The University Of California Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)
US8512944B2 (en) 2008-08-27 2013-08-20 Oncotherapy Science, Inc. PRMT1 for target genes of cancer therapy and diagnosis
US10138485B2 (en) 2008-09-22 2018-11-27 Rxi Pharmaceuticals Corporation Neutral nanotransporters
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
AU2011232365A1 (en) 2010-03-24 2012-10-25 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
CA2817218C (en) 2010-11-10 2020-02-18 Nigel L. Webb Nuclions and ribocapsids
RU2460517C1 (ru) * 2011-07-14 2012-09-10 Федеральное государственное учреждение "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Фармацевтическая композиция для комплексного лечения заболеваний глазной поверхности у больных с первичной открытоугольной глаукомой
IN2015DN02699A (pt) 2012-09-05 2015-09-04 Sylentis Sau
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
US8908303B1 (en) 2013-07-30 2014-12-09 Kabushiki Kaisha Toshiba Method for servo demodulation and disk storage apparatus
EP2865757A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
EP2865758A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene
SG11201605247XA (en) 2013-12-27 2016-08-30 Bonac Corp Artificial match-type mirna for controlling gene expression and use therefor
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US10011837B2 (en) 2014-03-04 2018-07-03 Sylentis Sau SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
WO2015168108A2 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic targeting mdm2 or mycn
JP2017514908A (ja) * 2014-05-01 2017-06-08 アールエックスアイ ファーマシューティカルズ コーポレーション 核酸分子を利用する目の前部における障害の処置のための方法
CN107109415B (zh) 2014-12-27 2021-07-09 株式会社博纳克 控制基因表达的天然型miRNA及其用途
FR3031503A1 (fr) * 2015-01-14 2016-07-15 Qualipac Sa Recipient, composant de recipient, et gamme de tels produits
WO2016158809A1 (ja) 2015-03-27 2016-10-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
MX2018008086A (es) * 2015-12-29 2018-11-12 Univ Hokkaido Nat Univ Corp Molecula de acido nucleico monocatenario que inhibe la expresion del gen de prorrenina o el gen del receptor de prorrenina y uso de la misma.
US10799676B2 (en) 2016-03-21 2020-10-13 Edwards Lifesciences Corporation Multi-direction steerable handles for steering catheters
CN106267222B (zh) * 2016-09-12 2020-05-19 北京市心肺血管疾病研究所 血管紧张素ⅱ用于改善大分子药物或药物载体的心脏递送
CN106228753A (zh) * 2016-09-30 2016-12-14 福建工程学院 一种意外摔倒监控方法、***及终端
CN110650624A (zh) * 2017-03-10 2020-01-03 威斯康星州医药大学股份有限公司 用于视网膜疾病的核糖开关调节的基因治疗
JP2017200928A (ja) * 2017-05-31 2017-11-09 シレンティス・エセ・ア・ウ ｓｉＲＮＡならびに眼の状態の処置および／または予防のための方法および組成物におけるその使用
CN113474041A (zh) * 2018-11-29 2021-10-01 奥哈伊视网膜技术有限责任公司 基于rpe黑色素水平的确定来安全提供视网膜光疗的方法
CN113646432A (zh) 2019-01-23 2021-11-12 雷杰纳荣制药公司 用血管生成素样7(angptl7)抑制剂治疗眼科疾病
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
US20210348234A1 (en) * 2020-02-24 2021-11-11 The Board Of Regents Of The University Of Texas System Molecular biomarkers and targets for fuches' endothelial corneal dystrophy and glaucoma
WO2021206917A1 (en) * 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021255262A1 (en) 2020-06-19 2021-12-23 Sylentis Sau siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
WO2022182768A1 (en) 2021-02-26 2022-09-01 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343794A (en) 1980-05-06 1982-08-10 Mt. Sinai Method of reducing intraocular pressure with salts of vanadic acid
US4652586A (en) 1980-11-07 1987-03-24 The General Hospital Corporation Selective beta-2 adrenergic antagonists for the treatment of glaucoma
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US5242943A (en) 1984-03-28 1993-09-07 William J. Louis 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
US4812448A (en) * 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4757089A (en) * 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
US5260059A (en) * 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5464866A (en) * 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US20020055536A1 (en) 1996-09-26 2002-05-09 Dewitte Robert S. System and method for structure-based drug design that includes accurate prediction of binding free energy
US6489307B1 (en) 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6365576B1 (en) 1999-06-24 2002-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for inhibiting herpes infection
CZ302719B6 (cs) 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
US20020165158A1 (en) 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070049543A1 (en) 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
AU2002361861A1 (en) 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
GB2406568B (en) 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
JP2006500910A (ja) * 2002-04-18 2006-01-12 アキュイティ ファーマシューティカルズ、インク． Ｃｎｓと眼の標的遺伝子を特異的に調節するための手段と方法及びその同定法
MXPA04009471A (es) 2002-04-30 2005-01-25 Alcon Inc Agentes que regulan, inhiben o modulan la actividad y/o expresion de factor de crecimiento de tejido de conexion (ctgf) como un medio unico para ambos reducir la presion intraocular y tratar retinopatias glaucomatosas/neuropatias opticas.
US20040115641A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
CA2493251A1 (en) 2002-07-24 2004-01-29 Immusol Incorporated Single promoter system for making sirna expression cassettes and expression libraries using a polymerase primer hairpin linker
CA2493564A1 (en) 2002-07-24 2004-01-29 Immusol, Inc. Novel sirna libraries and their production and use
ATE350473T2 (de) 2002-08-05 2007-01-15 Atugen Ag Weitere neue formen von interferierende rns moleküle
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
CA2881743A1 (en) 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
US7521431B2 (en) 2002-11-01 2009-04-21 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
CN1498964A (zh) 2002-11-07 2004-05-26 本元正阳基因技术股份有限公司 可诱导RNAi途径的用于基因治疗的系列重组腺相关病毒
ATE517992T1 (de) * 2002-11-14 2011-08-15 Dharmacon Inc Funktionelle und hyperfunktionelle sirna
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20060257851A1 (en) * 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US20040167090A1 (en) 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
GB0307206D0 (en) 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US7462602B2 (en) 2003-05-01 2008-12-09 University Of Florida Research Foundation, Inc. Anti-scarring ribozymes and methods
US20040224405A1 (en) 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
US20060241072A1 (en) 2003-06-20 2006-10-26 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
BRPI0415167A (pt) 2003-10-07 2006-11-28 Renovis Inc composto de amina como ligandos de canal de ìon e usos dos mesmos
GB0324334D0 (en) 2003-10-17 2003-11-19 Pilkington Plc Load bearing laminates
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050208658A1 (en) * 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
US20090247604A1 (en) * 2004-02-05 2009-10-01 Intradigm Corporation RNAi Therapeutics for Treatment of Eye Neovascularization Diseases
GB0403600D0 (en) * 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
EP2636739B1 (en) 2004-03-12 2014-12-10 Alnylam Pharmaceuticals Inc. iRNA agents targeting VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005117938A2 (en) * 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
EP2322650A1 (en) 2004-05-14 2011-05-18 Rosetta Genomics Ltd MicroRNAs and uses thereof
EP1768954A4 (en) * 2004-06-24 2008-05-28 Incyte Corp 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS
CA2576233C (en) 2004-08-10 2016-03-15 Alnylam Pharmaceuticals, Inc. Conjugate comprising an antagomir and a ligand
PL1781787T3 (pl) 2004-08-23 2018-01-31 Sylentis Sau Leczenie zaburzeń oka charakteryzowanych przez podwyższone ciśnienie wewnątrzgałkowe przy użyciu siRNA
GB0421169D0 (en) 2004-09-23 2004-10-27 Securis Ltd Apparatus and process for the printing of microstructures
TW200639253A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
AU2006223131A1 (en) 2005-03-11 2006-09-21 Alcon, Inc. RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
US7621431B2 (en) * 2005-04-06 2009-11-24 Chicco Usa, Inc. Folding stroller tray
KR101283539B1 (ko) * 2007-08-29 2013-07-15 삼성전자주식회사 역전 구조의 비휘발성 메모리 소자, 그 스택 모듈 및 그제조 방법

Also Published As

Publication number Publication date
EP2292757A3 (en) 2011-11-16
AU2005276245A1 (en) 2006-03-02
AU2005276245B2 (en) 2010-06-03
EP2298892A2 (en) 2011-03-23
US20100331394A1 (en) 2010-12-30
LT1781787T (lt) 2017-07-25
DK1781787T3 (en) 2017-07-31
US20060234970A1 (en) 2006-10-19
US8247386B2 (en) 2012-08-21
SI1781787T1 (sl) 2017-08-31
WO2006021817A2 (en) 2006-03-02
EP2292757A2 (en) 2011-03-09
EP2298892A3 (en) 2011-11-16
US8247387B2 (en) 2012-08-21
CA2578064A1 (en) 2006-03-02
HRP20171010T8 (hr) 2017-11-03
CY1119061T1 (el) 2018-01-10
AU2005276245C1 (en) 2015-02-26
US8198250B2 (en) 2012-06-12
JP5766900B2 (ja) 2015-08-19
JP2012205594A (ja) 2012-10-25
US20100022623A1 (en) 2010-01-28
US8252758B2 (en) 2012-08-28
PL1781787T3 (pl) 2018-01-31
CN102895673A (zh) 2013-01-30
EP1781787A2 (en) 2007-05-09
US8951982B2 (en) 2015-02-10
US8252759B2 (en) 2012-08-28
HRP20171010T1 (hr) 2017-09-22
JP2008510786A (ja) 2008-04-10
US20090099111A1 (en) 2009-04-16
US8258110B2 (en) 2012-09-04
WO2006021817A3 (en) 2006-06-08
CA2578064C (en) 2015-10-13
US20090105176A1 (en) 2009-04-23
CN105251024A (zh) 2016-01-20
HUE033977T2 (en) 2018-02-28
US7902169B2 (en) 2011-03-08
US20070270365A1 (en) 2007-11-22
US20090105175A1 (en) 2009-04-23
US20090099112A1 (en) 2009-04-16
US8389490B2 (en) 2013-03-05
US20090099113A1 (en) 2009-04-16
EP1781787B1 (en) 2017-04-12
US8030284B2 (en) 2011-10-04
US20090099114A1 (en) 2009-04-16
ES2632913T3 (es) 2017-09-18
RU2407531C2 (ru) 2010-12-27
US20140018527A1 (en) 2014-01-16
US7592325B2 (en) 2009-09-22
RU2007110646A (ru) 2008-09-27

Similar Documents

Publication Publication Date Title
HRP20171010T8 (hr) Liječenje poremećaja očiju koji su karakterizirani povišenim intraokularnim pritiskom pomoću sirnk
HK1254088A1 (zh) 用於治療老花眼和其他眼疾的鞏膜假體
EP3351211C0 (en) SCLERAL PROSTHESIS TO TREAT PRESBYOPIA AND OTHER EYE DISORDERS
ZA200704932B (en) Rnai inhibition of CTGF for treatment of ocular disorders
EP1732484A4 (en) OPHTHALMIC IMPLANT FOR THE TREATMENT OF GLAUCOMA
EP1933751A4 (en) INTRASTROMAL REFRACTIVE SURGERY BY INDUCTION OF SHAPE CHANGES IN THE HORN SKIN
HK1201046A1 (en) Methods of treating ophthalmic diseases
EP1711510A4 (en) THERAPY WITH RNAI AGENTS APPLIED IN THE TREATMENT OF OCULAR DISEASES RESULTING FROM NEOVASCULARIZATION
EP2059282A4 (en) APPARATUS, METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISORDERS
PL383268A1 (pl) Kompozycje oftalmiczne i sposoby leczenia oczu
PL2444079T3 (pl) Kompozycje i sposoby leczenia chorób oczu
EP2020970A4 (en) TREATMENT OF THE EYE
IL209948A0 (en) Method of eye treatment for prevention of presbyopia and glaucoma, and means for carrying out said treatment
PT2056863T (pt) Tratamento de doenças oculares
GB0523961D0 (en) The treatment of ophthalmic diseases
HK1143945A1 (en) Scleral prosthesis having crossbars for treating presbyopia and other eye disorders
EP2296682B8 (en) Methods of treating ophthalmic disorders
EP2083841A4 (en) TREATMENT OF MACULAR DEGENERATION FROM AGING AND OTHER OCULAR DISEASES
GB0414772D0 (en) Ophthalmic eye preparation
GB2433322B (en) Statistical control of adaptive ocular filter stability
GB0523964D0 (en) The treatment of ophthalmic diseases
ZA200807828B (en) Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
PT2155733E (pt) Lactamas cíclicas para o tratamento de glaucoma ou pressão intra-ocular elevada
IL208831A0 (en) Methods of treating ophthalmic disorders
AU2004905035A0 (en) Treatment of Ophthalmic Conditions